Table 2. Univariate and multivariate analyses of overall survival among patients with uterine sarcoma.
| Characteristics | No. of patients | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |||
| MSLN expression | ||||||
| Low | 79 | 1.00 | ||||
| High | 40 | 0.48 (0.26–0.89) | 0.016 | 0.29 (0.15–0.57) | <0.001 | |
| Age (yr) | ||||||
| <63 | 62 | 1.00 | ||||
| ≥63 | 57 | 1.53 (0.91–2.57) | 0.111 | 1.94 (1.13–3.35) | 0.017 | |
| Stage | ||||||
| I/II | 56 | 1.00 | ||||
| III/IV | 63 | 2.22 (1.29–3.82) | 0.003 | 3.51 (1.97–6.25) | <0.001 | |
| ECOG PS | ||||||
| 0 | 108 | 1.00 | ||||
| 1 | 11 | 1.52 (0.69–3.35) | 0.328 | 1.88 (0.80–4.41) | 0.146 | |
| Carcinoma component | ||||||
| Endometrioid | 54 | 1.00 | ||||
| Serous | 34 | 1.36 (0.72–2.57) | 0.341 | |||
| Others | 31 | 1.66 (0.90–3.08) | 0.104 | |||
| Sarcoma component | ||||||
| Homologous | 70 | 1.00 | ||||
| Heterologous | 49 | 1.49 (0.89–2.50) | 0.133 | |||
| HER2 status | ||||||
| Negative | 32 | 1.00 | ||||
| Low | 40 | 0.87 (0.46–1.62) | 0.655 | |||
| High | 46 | 0.61 (0.32–1.16) | 0.129 | |||
| Chemotherapy | ||||||
| No | 53 | 1.00 | ||||
| Yes | 66 | 1.17 (0.70–1.99) | 0.559 | |||
CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Groups performance status; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; MSLN, mesothelin.